TABLE 1.

Direct Oral Anticoagulants^21–26

Anticoagulant	Indications	FDA-Approved Reversal Agent
FXa inhibitors
Rivaroxaban	To reduce the risk of SSE in patients with NVAF For the treatment of DVT and PE For the reduction in the risk of recurrence of DVT and of PE following the initial 6 months treatment for DVT and/or PE For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery	None
Apixaban	To reduce the risk of SSE in patients with NVAF For the prophylaxis of DVT, which may lead to PE in patients who have undergone hip or knee replacement surgery For the treatment of DVT and PE To reduce the risk of recurrent DVT and PE following initial therapy	None
Edoxaban	To reduce the risk of SSE in patients with NVAF For the treatment of DVT and PE following 5 to 10 days of initial therapy with a parenteral anticoagulant	None
Betrixaban	Investigational agent; not yet FDA-approved. Being investigated for extended-duration, hospital-associated prevention of VTE in acute medically ill patients.	None
Thrombin Inhibitor
Dabigatran	To reduce the risk of SSE in patients with NVAF For the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for 5 to 10 days To reduce the risk of recurrence of DVT and PE in patients who have been previously treated For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery	Idarucizumab

DVT indicates deep vein thrombosis; FXa, factor Xa; NVAF, nonvalvular atrial fibrillation; PE, pulmonary embolism; SSE, stroke or systemic embolism; VTE, venous thromboembolism.